A phase 1/2a, dose-escalation, safety, and preliminary efficacy study of the RKP00156 vaginal tablet in healthy women and patients with cervical intraepithelial neoplasia 2.

Published in: Journal of gynecologic oncology (2024)

ClinicalTrials.gov Identifier: NCT02139267.

Keyphrases